Showing results (101-110 of 140) with videos related to
Sort By:
Pageof 14
Lung Cancer (Amsterdam, Netherlands)|September 11, 2010
Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancerAkito Hata, Nobuyuki Katakami, Shiro Fujita, et al.Case Reports in Oncology|August 27, 2010
Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene MutationKatsuhiro Masago, Yosuke Togashi, Masahide Fukudo, et al.Internal Medicine (Tokyo, Japan)|December 7, 2007
Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung diseaseKeiichiro Sakuma, Hajime Nakamura, Takayuki Nakamura, et al.Cancer Genetics|October 10, 2025
Identification of novel gene fusions in high-grade serous ovarian carcinoma: implications for tumorigenesis and targeted therapyKatsuhiro Masago, Eiichi Sasaki, Yasuko Fujita, et al.Oncology|March 25, 2011
Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinibKatsuhiro Masago, Shiro Fujita, Yosuke Togashi, et al.Case Reports in Oncology|September 17, 2010
Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung CancerAkiko Fukuhara, Katsuhiro Masago, Masashi Neo, et al.Cancer Science|August 10, 2020
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancerYusuke Kagawa, Hiromi Furuta, Takehiro Uemura, et al.Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancerTerufumi Kato, Noriyuki Masuda, Yoichi Nakanishi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Novel Resistance Mechanisms Including L1196Q, P1094H, and R1248_D1249 Insertion in Three Patients With NSCLC After ALK Tyrosine Kinase Inhibitor TreatmentHiromi Furuta, Mitsugu Araki, Katsuhiro Masago, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2010
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysisYosuke Togashi, Katsuhiro Masago, Masahide Fukudo, et al.Pageof 14